L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, CA Cancer J Clin, vol.65, p.25651787, 2012.

N. Howlader, A. M. Noone, M. Krapcho, D. Miller, K. Bishop et al., SEER data submission, posted to the SEER web site, National Cancer Institute. Bethesda, MD, 1975.

C. Swanton and R. Govindan, Clinical Implications of Genomic Discoveries in Lung Cancer, N Engl J Med, vol.374, pp.1864-1873, 2016.

Z. Chen, C. M. Fillmore, P. S. Hammerman, C. F. Kim, and K. Wong, Non-small-cell lung cancers: a heterogeneous set of diseases, Nat Rev Cancer, vol.14, p.25056707, 2014.

E. Heitzer, P. Ulz, and J. B. Geigl, Circulating tumor DNA as a liquid biopsy for cancer, Clin Chem, vol.61, pp.112-123, 2015.

D. Mattos-arruda, L. Weigelt, B. Cortes, J. Won, H. H. Ng et al., Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle, Ann Oncol, vol.25, pp.1729-1735, 2014.

E. Izumchenko, X. Chang, M. Brait, E. Fertig, L. T. Kagohara et al., Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA, Nat Commun, vol.6, p.8258, 2015.

S. Dawson, D. Tsui, M. Murtaza, H. Biggs, O. M. Rueda et al., Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer, N Engl J Med, vol.368, pp.1199-1209, 2013.

M. Murtaza, S. Dawson, K. Pogrebniak, O. M. Rueda, E. Provenzano et al., Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer, Nat Commun, vol.6, p.8760, 2015.

Y. Lo, J. Zhang, T. N. Leung, T. K. Lau, A. Chang et al., Rapid Clearance of Fetal DNA from Maternal Plasma, Am J Hum Gen, vol.64, pp.218-224, 1999.

F. Diehl, K. Schmidt, M. A. Choti, K. Romans, S. Goodman et al., Circulating mutant DNA to assess tumor dynamics, Nat Med, vol.14, pp.985-990, 2008.

M. Qiu, J. Wang, Y. Xu, X. Ding, M. Li et al., Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis, Cancer Epidemiol Biomarkers Prev, vol.24, pp.206-212, 2015.

J. Douillard, G. Ostoros, M. Cobo, T. Ciuleanu, R. Cole et al., Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status, J Thorac Oncol, vol.9, pp.1345-1353, 2014.

N. Karachaliou, C. Mayo-de-las-casas, C. Queralt, I. De-aguirre, B. Melloni et al., Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial, JAMA Oncol, vol.1, pp.149-157, 2015.

J. Uchida, K. Kato, Y. Kukita, T. Kumagai, K. Nishino et al., Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA, Clin Chem, vol.61, pp.1191-1196, 2015.

A. G. Sacher, C. Paweletz, S. E. Dahlberg, R. S. Alden, A. O'connell et al., Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer, JAMA Oncol, pp.1-14, 2016.

G. R. Oxnard, C. P. Paweletz, Y. Kuang, S. L. Mach, A. O'connell et al., Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA, Clin Cancer Res, vol.20, p.24429876, 2014.

K. S. Thress, C. P. Paweletz, E. Felip, B. C. Cho, D. Stetson et al., Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat Med, vol.21, p.25939061, 2015.

K. S. Thress, R. Brant, T. H. Carr, S. Dearden, S. Jenkins et al., EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291, Lung Cancer, vol.90, pp.509-515, 2015.

D. Zheng, X. Ye, M. Z. Zhang, Y. Sun, J. Y. Wang et al., Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance, Sci Rep, vol.6, p.20913, 2016.

A. R. Thierry, F. Mouliere, M. El, S. Mollevi, C. Lopez-crapez et al., Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nat Med, vol.20, pp.430-435, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02168071

V. Taly, D. Pekin, L. Benhaim, S. K. Kotsopoulos, L. Corre et al., Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, p.23938455, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299581

F. Diehl, M. Li, D. Dressman, Y. He, D. Shen et al., Detection and quantification of mutations in the plasma of patients with colorectal tumors, Proc Natl Acad Sci U S A, vol.102, pp.16368-16373, 2005.

T. Forshew, M. Murtaza, C. Parkinson, D. Gale, D. Tsui et al., Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA, Sci Transl Med, vol.4, p.22649089, 2012.

I. Kinde, J. Wu, N. Papadopoulos, K. W. Kinzler, and B. Vogelstein, Detection and quantification of rare mutations with massively parallel sequencing, Proc Natl Acad Sci U S A, vol.108, p.21586637, 2011.

J. Tie, I. Kinde, Y. Wang, H. L. Wong, J. Roebert et al., Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann Oncol, vol.26, p.25851626, 2015.

N. Pécuchet, Y. Rozenholc, E. Zonta, D. Pietraz, A. Didelot et al., Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA, Clin Chem, vol.62, p.27624137, 2016.

D. E. Gerber, S. E. Dahlberg, A. B. Sandler, D. H. Ahn, J. H. Schiller et al., Baseline tumour measurements predict survival in advanced non-small cell lung cancer, Br J Cancer, vol.109, pp.1476-1481, 2013.

C. A. Milbury, Q. Zhong, J. Lin, M. Williams, J. Olson et al., Determining lower limits of detection of digital PCR assays for cancer-related gene mutations, Biomol Detect Quantif, vol.1, pp.8-22, 2014.

A. Mckenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data, Genome Res, vol.20, p.20644199, 2010.

F. Barlési, J. Mazieres, J. Merlio, D. Debieuvre, J. Mosser et al., Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet, vol.387, pp.1415-1426, 2016.

S. R. Whittaker, J. Theurillat, E. Van-allen, N. Wagle, J. Hsiao et al., A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition, Cancer Discov, vol.3, pp.350-362, 2013.

Y. Tong, B. Zhang, Y. Fan, and N. Lin, Keap1-Nrf2 pathway: A promising target towards lung cancer prevention and therapeutics, Chronic Dis Transl Med, vol.1, pp.175-186, 2015.

A. M. Newman, S. V. Bratman, J. To, J. F. Wynne, N. Eclov et al., An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage, Nat Med, vol.20, p.24705333, 2014.

K. Saukkonen, P. Lakkisto, V. Pettila, M. Varpula, S. Karlsson et al., Cell-Free Plasma DNA as a Predictor of Outcome in Severe Sepsis and Septic Shock, Clin Chem, vol.54, pp.1000-1007, 2008.

T. Mok, Y. Wu, J. S. Lee, C. Yu, V. Sriuranpong et al., Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy, Clin Cancer Res, vol.21, pp.3196-3203, 2015.

J. Y. Lee, X. Qing, W. Xiumin, B. Yali, C. S. Bak et al., Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02), Oncotarget, vol.7, pp.6984-6993, 2016.